CARVYKTI (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

26.05.2022 - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission (EC) has ...

Related Keywords

New Jersey ,United States ,China ,Germany ,Japan ,Hermann Einsele ,Ying Huang ,Linkedin ,Janssen Biotech Inc ,Twitter ,European Commission ,Drug Administration ,Medicinal Devices Agency ,Julius Maximilian University ,Legend Biotech Corporation ,Committee For Orphan Medicinal Products ,European Medicines Agency ,Chief Executive Officer ,Full Professor ,Internal Medicine ,Medizinische Klinik ,Legend Biotech ,Janssen Biotech ,Marketing Authorisation Application ,Therapy Designation ,Breakthrough Therapy Designation ,Orphan Drug Designation ,Orphan Medicinal Products ,